Respiratory examination, basic investigations and therapeutics Dr Felix Woodhead Consultant Respiratory Physician
Examination General appearance –Smoker –BMI –Tattoos etc –Other diseases (RA etc) Clubbing and Lymph nodes Trachea, apex etc (mediastinal shift) Scars Unilateral vs bilateral
Examination –Unilateral changes crackles: –Pneumonia –localised bronchiectasis –‘LRTI’ Bronchial breathing –consolidation, –severe fibrosis, –anterior chest Wheeze: localised stricture (never heard!) Reduced air entry –Collapse –effusion
Examination –Bilateral changes Wheeze (obstructive disease) –Asthma –COPD –Bronchiectasis Crackles –Pulmonary oedema:moist –Bronhiectasis:moist, pt coughing –Interstitial disease:Velcro, ‘hair-on-end’
Investigations Physiology –Peak flow meter –Spirometry –‘Full lung function’ Spirometry Lung Volumes Gas transfer Radiology –PA CXR –CT (spiral vs HRCT)
Spirometry and PFTs
Spirometry Measure Volume (bellows) or Flow (turbine), derive one from the other FEV 1 and FVC FEV 1 /FVC ratio cutoff 70% Calculate it yourself! <70% = obstructive –quantify by FEV 1 % predicted ≥70% = NORMAL or restrictive –quantify by FVC % predicted Graph allows assessment of blow technique Better assessed by Flow/volume loop
Typical graphs
Other components of PFTs Static lung volumes –He dilution –Body plethysmography –TLC & RV –↑ in obstructive lung disease (esp emphysema) –↓ in restrictive disease Gas transfer –TLco ≡ DLco –Kco = TLco/V A –↓ in alveolar/interstitial damage (emphysema & ILD)
Restrictive Defect “Small lungs” vs “Wheezy lungs” (obstructive) Intrinsic lung disease –abnormal radiology –↓TLco Extrathoracic restriction –normal radiology –normal TLco –? ↑Kco (↓V A → TLco/V A ↑)
Extrathoracic Restriction Soft tissues –Obesity –BMI not weight Muscles –Diaphragm > intercostals –Orthopnoea –Sitting/lying FVC Thoracic cage –Scoliosis > kyphosis Pleural thickening
Respiratory Therapeutics Dr Felix Woodhead Consultant Respiratory Physician
Airways
Delivery methods Nebulisers Inhalers –Aerosol –Dry powder –Proprietary types
Drugs Bronchodilators
β 2 agonists Short-acting –Salbutamol –Terbutaline Long-acting –Salmeterol –Formoterol
Antimuscarinics Short-acting –ipratropium Long-acting –tiotropium
Steroids Beclomethasone Budesonide Fluticasone Small- particle BCZ
Combined agents Seretide (Purple) –=serevent (salmeterol) + flixotide (fluticasone) –Evohaler (MDI) or accuhaler (DPI) Symbicort –Oxis (formoterol) + pulmicort (budesonide) –Turbohaler (DPI) –SMART regime
Systemic agents
Asthma β 2 agonists –Paediatrics –Occ IV Theophyllines –IV –Oral sustained release leukotriene-receptor antagonists –Monteleukast/zafirleukast Omalizumab
Antibiotics
Gram positive infections Penicillins –Amoxicillin –Co-amoxiclav –Piperacillin/tazobactam Macrolides –Erythromycin –Clarithromycin –Azithromycin
Gram negative infections Quinolones –Ciprofloxacin –Moxifloxacin Aminoglycosides –Gentamicin –Tobramycin –Amikacin
Prophylactic antibiotics Oral –Azithromycin –Others Nebulised –Aminoglycosides –Colistin
Immunosuppressants
Steroid Prednisolone –Dose –weaning Hydrocortisone (Dexamethasone) Methylprednisolone
Azathioprine Dosing –1 mg/kg/day first 1/12 with weekly FBC/LFTs –2 mg/kg/day thereafter. Bloods every 6/52 TPMG –Thiopurine methyltransferase –Reduce dose if low expression –Avoid Aza if absent levels
Methotrexate Widely used outside respiratory Generally avoided because of potential pulmonary toxicity ?useful in eg sarcoid